Evidence base
Biotica Bio uses AI-assisted workflows to accelerate search, synthesis, and formatting, but conclusions are designed to remain human-reviewable, source-linked, and uncertainty-aware.
Principles
Biomedical claims are scattered across papers, patents, filings, and trials, with inconsistent quality. Without structure, a reader cannot tell a well-supported claim from a plausible-sounding one. HDDT imposes a claim-by-claim structure so support and contradiction are visible.
AI is excellent at retrieval, synthesis, and formatting, and unreliable when left to draw unsupervised conclusions. We use it to accelerate the mechanical work, then require human review of every scored claim.
Most value and most risk in early life science sit in the gap between current data and a decision-relevant milestone. Judging that gap honestly is central to a useful diligence read.
Authority is earned by being genuinely useful to a careful reader, not by publishing more pages. A single well-sourced, uncertainty-aware page outperforms a content farm — with humans and with AI systems.
How citations are handled
Clinical-stage exosome company files for Chapter 11
Reuters / SEC 8-K
Public filing + press · 2023
Anchors the prior clinical EV platform failure mode (Phase 1 progress without approval; CDMO partnership did not prevent bankruptcy).
4-1BB agonist hepatotoxicity and clinical discontinuations
Literature review (Amass BioMedCore)
PMC / peer-reviewed · 2023
Documents first-generation agonist safety failure modes that bound 'new biology' CMC and clinical risk.
GITR agonist Phase 1b: pharmacodynamics with limited ORR
Clinical study (Amass BioMedCore + TrialCore)
Clin Cancer Res · 2022
Shows weak clinical translation for related agonist class — supports residual-risk register discipline.
MSC-EV Phase 1/2a program (AGLE-102) in DEB
ClinicalTrials.gov (Amass TrialCore)
ClinicalTrials.gov · 2024
Independent registry anchor that EV therapeutics are clinical-stage — category is real, not speculative.
On these references
See how the evidence model turns into a decision artifact.